Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18166882 | 0.93 | — | — | |
| SCHEMBL8677447 | 0.86 | — | — | |
| SCHEMBL11074782 | 0.86 | — | — | |
| SCHEMBL18725844 | 0.86 | — | — | |
| SCHEMBL11563602 | 0.86 | — | — | |
| SCHEMBL23949122 | 0.83 | MAOA (0.35) | — | |
| SCHEMBL646169 | 0.80 | PTGS2 (0.34) | — | |
| SCHEMBL23948581 | 0.80 | — | — | |
| SCHEMBL2589165 | 0.78 | PTGS2 (0.36) | — | |
| SCHEMBL2581422 | 0.78 | PTGS2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135501-A1 | MONO-SUBSTITUTED CYCLOPENTADIENES AND METAL CYCLOPENTADIENYL COMPLEXES AND SYNTHESIS METHODS THEREOF | LARI LIQUIDE SOC ANOYME POUR IETUDE ET IEXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2022-05-05 | — | — | US | disclosed |
| US-20220048837-A1 | MONO-SUBSTITUTED CYCLOPENTADIENES AND METAL CYCLOPENTADIENYL COMPLEXES AND SYNTHESIS METHODS THEREOF | L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude (FR) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135501-A1 | MONO-SUBSTITUTED CYCLOPENTADIENES AND METAL CYCLOPENTADIENYL COMPLEXES AND SYNTHESIS METHODS THEREOF | NR1H4, NR1H3, NR1H2 | NOS2 2240/4885 |
| US-20220048837-A1 | MONO-SUBSTITUTED CYCLOPENTADIENES AND METAL CYCLOPENTADIENYL COMPLEXES AND SYNTHESIS METHODS THEREOF | SOD1, SOD3, CAD | NOS2 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.